NextGen, GE earn PMS accreditation from EHNAC

GE Healthcare and NextGen Healthcare are the first two organizations to achieve accreditation under the Electronic Healthcare Network Accreditation Commission's (EHNAC) Practice Management System Accreditation Program (PMSAP).

Jointly developed with the Workgroup for Electronic Data Interchange (WEDI), PMSAP has been designed to serve as a third-party review and provide an additional level of assurance to the provider community during the evaluation process of PMS system vendors.

The accreditation program offers a comprehensive evaluation of practice management system (PMS) vendors in the areas of privacy, security, mandated standards and operating rules and key operational functions.

Additionally, the PMSAP assesses health information and oversight for meeting privacy and security, HIPAA and Affordable Care Act requirements, as well as focuses on technical performance, business processes and resource management. The program also provides a review of the PMS vendor readiness to support and implement ICD-10 in 2015 and therefore a level of assurance to the provider community.

As beta participants throughout the consultative and consensus-driven process of program development, GE Healthcare and NextGen Healthcare were the first to undergo evaluation on their compliance with the criteria and receive full accreditation status for the two-year timeframe, according to a release.

"As beta organizations for the PMS accreditation program, GE Healthcare and NextGen Healthcare's collaboration and feedback have been vital components in the development of an industry-changing initiative," said Lee Barrett, executive director of EHNAC. "The need to maintain high standards of privacy, security and confidentiality as a practice management system vendor is critical, to say the least."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.